Cytokinetics Announces Outcome of FDA Advisory Committee Vote On Omecamtiv Mecarbil

PDUFA Target Action Date is February 28, 2023 SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food& Drug Administration (FDA) Cardiovascular and Renal...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news